ClinicalTrials.gov record
Completed Phase 3 Interventional

Double-Blind, Randomized Study Of The Analgesic Efficacy And Safety Of Valdecoxib 20 Mg Daily And Valdecoxib 20 Mg Twice Daily Compared To Placebo For Management Of Acute Postsurgical Pain In Anterior Cruciate Ligament (ACL) Reconstruction

ClinicalTrials.gov ID: NCT00650039

Public ClinicalTrials.gov record NCT00650039. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Apr 27, 2026, 6:20 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Double-Blind, Placebo-Controlled, Randomized Study Of The Analgesic Efficacy And Safety Of Valdecoxib 20 Mg QD And Valdecoxib 20 Mg BID Compared To Placebo Over Multiple Days For Management Of Acute Postsurgical Pain In Patients Undergoing Anterior Cruciate Ligament Reconstruction

Study identification

NCT ID
NCT00650039
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Pfizer
Industry
Enrollment
488 participants

Conditions and interventions

Conditions

Interventions

  • placebo Drug
  • valdecoxib Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 75 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 29, 2004
Primary completion
Not listed
Completion
Jan 31, 2005
Last update posted
Jun 3, 2008

2004 – 2005

United States locations

U.S. sites
68
U.S. states
17
U.S. cities
49
Facility City State ZIP Site status
Pfizer Investigational Site Birmingham Alabama 35205
Pfizer Investigational Site Birmingham Alabama 36205
Pfizer Investigational Site Northport Alabama 35476
Pfizer Investigational Site Glendale Arizona 85310
Pfizer Investigational Site Pheonix Arizona 85006
Pfizer Investigational Site Pheonix Arizona 85008
Pfizer Investigational Site Pheonix Arizona 85016
Pfizer Investigational Site Phoenix Arizona 85016
Pfizer Investigational Site Phoenix Arizona 85032
Pfizer Investigational Site Tempe Arizona 85281
Pfizer Investigational Site Glendale California 91206
Pfizer Investigational Site Laguna Hills California 92653
Pfizer Investigational Site Laguna Woods California 92653
Pfizer Investigational Site Los Angeles California 90045
Pfizer Investigational Site Avon Connecticut 06001
Pfizer Investigational Site Cromwell Connecticut 06416
Pfizer Investigational Site Enfield Connecticut 06082
Pfizer Investigational Site Farmington Connecticut 06030
Pfizer Investigational Site Farmington Connecticut 06032
Pfizer Investigational Site Glastonbury Connecticut 06033
Pfizer Investigational Site Hartford Connecticut 06102
Pfizer Investigational Site Hartford Connecticut 06106
Pfizer Investigational Site Rocky Hill Connecticut 06067
Pfizer Investigational Site Windsor Connecticut 06095
Pfizer Investigational Site Hollywood Florida 33021
Pfizer Investigational Site Jacksonville Florida 32216
Pfizer Investigational Site Jacksonville Florida 32250
Pfizer Investigational Site Plantation Florida 33324
Pfizer Investigational Site Saint Augustine Florida 32086
Pfizer Investigational Site St. Petersburg Florida 33703
Pfizer Investigational Site Weston Florida 33326
Pfizer Investigational Site Atlanta Georgia 30327
Pfizer Investigational Site Morrow Georgia 30260
Pfizer Investigational Site Stockbridge Georgia 30281
Pfizer Investigational Site Chicago Illinois 60304
Pfizer Investigational Site Chicago Illinois 60612
Pfizer Investigational Site Oak Park Illinois 60304
Pfizer Investigational Site Cedar Rapids Iowa 52401
Pfizer Investigational Site Lexington Kentucky 40504
Pfizer Investigational Site Lexington Kentucky 40509
Pfizer Investigational Site Baltimore Maryland 21218
Pfizer Investigational Site Timonium Maryland 21093
Pfizer Investigational Site Royal Oak Michigan 48073
Pfizer Investigational Site Troy Michigan 48085
Pfizer Investigational Site Springfield Missouri 65804
Pfizer Investigational Site Springfield Missouri 65807
Pfizer Investigational Site Las Vegas Nevada 89106
Pfizer Investigational Site Las Vegas Nevada 89117
Pfizer Investigational Site Las Vegas Nevada 89121
Pfizer Investigational Site Las Vegas Nevada 89144
Pfizer Investigational Site Bend Oregon 97701
Pfizer Investigational Site Anderson South Carolina 29621
Pfizer Investigational Site Cola South Carolina 29212
Pfizer Investigational Site Columbia South Carolina 29202
Pfizer Investigational Site Columbia South Carolina 29204
Pfizer Investigational Site Orangeburg South Carolina 29110
Pfizer Investigational Site Austin Texas 78705
Pfizer Investigational Site Dallas Texas 75231
Pfizer Investigational Site Fort Worth Texas 76104
Pfizer Investigational Site Fort Worth Texas 76107
Pfizer Investigational Site San Antonio Texas 78127
Pfizer Investigational Site San Antonio Texas 78209
Pfizer Investigational Site San Antonio Texas 78217
Pfizer Investigational Site San Antonio Texas 78229
Pfizer Investigational Site San Antonio Texas 78240
Pfizer Investigational Site San Marcos Texas 78666
Pfizer Investigational Site Arlington Virginia 22205
Pfizer Investigational Site Fairfax Virginia 22031

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 13 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00650039, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 3, 2008 · Synced Apr 27, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00650039 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →